163
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
139
Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, Shilli-
day BB, DeWalt DA, Pignone MP. Predictors of opioid missues in patients with chronic
pain: a prospective cohort study. BMC Health Services Research 2006; 6: 46.
140
Jacobsen R, Moldrup C, Christrup L. Clinical rationale for administering fentanyl to can-
cer pain patients: two Delphi surveys of pain management experts in Denmark. J Opioid
Manag 2008; 4 (6): 383-391.
141
Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics
of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid
Manage 2010; 6: 17-26.
142
Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous
morphine in the management of cancer pain: a double-blind cross-over study. Pain
1996; 67: 443-449.
143
Kanpolat Y, Savas A, Ucar T, Torun F. CT-guided percutaneous selective cordotomy for
treatment of intractable pain in patients with malignant pleural mesothelioma. Acta
Neurochirurgica 2002; 144: 595-599.
144
Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Ci-
cero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslick J, Lande SD. Foundations of opioid
risk management. Clinical Journal of Pain 2007; 23: 103-118.
145
Keating HJ, Kundrat M. Patient-controlled analgesia with nitrous oxide in cancer pain.
Journal of Pain and Symptom Management 1996; 11(2): 126-130.
146
Klepstad P, Kaasa S, Borchgrevink PC. Starting step III opioids for moderate to severe
pain in cancer patients: dose titration: a systematic review. Palliat Med 2011; 25(5):
424-430.
147
Krainick JU, Thoden U. Experience with dorsal column stimulation (DSC) in the opera-
tive treatment of chronic intractable pain. Journal of Neurosurgical Sciences 1974; 18:
187-189.
148
Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability
of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with
cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, cross-
over trial with a 10-month, open-label extension treatment period. Clin Ther 2009;
31(6): 1177-1191.
149
Laverty D. Actiq: an effective oral treatment for cancer related breakthrough pain. Br J
Community Nurs 2007; 12(7): 311.
150
Laverty D. Treating cancer-related breakthrough pain: the oral transmucosal route. Int J
Palliat Nurs 2007; 13(7): 326-331.
151
Laverty DM Davies A. Assessment. In: Davies AN (Hrsg.), Cancer-related breakthrough
pain. Oxford: Oxford University Press; 2006. p. 23-30.
152
Lawrie I, Lloyd-Williams M, Waterhouse E. Breakthrough strong opioid analgesia
prescription in patients using transderaml fentanyl admitted to a hospice. American
Journal of Hospice and Palliative Care 2003; 20: 229-230.
Literaturverzeichnis